DexCom Valuation
| DC4 Stock | EUR 73.98 0.63 0.86% |
At this time, the firm appears to be overvalued. DexCom Inc shows a prevailing Real Value of €59.77 per share. The current price of the firm is €73.98. Our model computes the value of DexCom Inc from reviewing the firm fundamentals such as Current Valuation of 42.38 B, profit margin of 0.12 %, and Shares Outstanding of 386.41 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that DexCom's price fluctuation is very steady at this time. Calculation of the real value of DexCom Inc is based on 3 months time horizon. Increasing DexCom's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the DexCom stock is determined by what a typical buyer is willing to pay for full or partial control of DexCom Inc. Since DexCom is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DexCom Stock. However, DexCom's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 73.98 | Real 59.77 | Hype 73.98 | Naive 71.57 |
The real value of DexCom Stock, also known as its intrinsic value, is the underlying worth of DexCom Inc Company, which is reflected in its stock price. It is based on DexCom's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of DexCom's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of DexCom Inc helps investors to forecast how DexCom stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DexCom more accurately as focusing exclusively on DexCom's fundamentals will not take into account other important factors: DexCom Total Value Analysis
DexCom Inc is currently estimated to have takeover price of 42.38 B with market capitalization of 40.57 B, debt of 1.2 B, and cash on hands of 1.38 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the DexCom fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
42.38 B | 40.57 B | 1.2 B | 1.38 B |
DexCom Investor Information
About 100.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings (P/E) ratio of 191.84. DexCom Inc had not issued any dividends in recent years. The entity had 4:1 split on the 13th of June 2022. DexCom Inc is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.DexCom Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. DexCom has an asset utilization ratio of 53.97 percent. This implies that the Company is making €0.54 for each dollar of assets. An increasing asset utilization means that DexCom Inc is more efficient with each dollar of assets it utilizes for everyday operations.DexCom Ownership Allocation
DexCom Inc retains a total of 386.41 Million outstanding shares. The majority of DexCom Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in DexCom Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in DexCom. Please pay attention to any change in the institutional holdings of DexCom Inc as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.DexCom Profitability Analysis
The company reported the revenue of 2.91 B. Net Income was 341.2 M with profit before overhead, payroll, taxes, and interest of 1.88 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates DexCom's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in DexCom and how it compares across the competition.
About DexCom Valuation
The stock valuation mechanism determines DexCom's current worth on a weekly basis. Our valuation model uses a comparative analysis of DexCom. We calculate exposure to DexCom's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of DexCom's related companies.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. DEXCOM INC operates under Diagnostics Research classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2800 people.
8 Steps to conduct DexCom's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates DexCom's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct DexCom's valuation analysis, follow these 8 steps:- Gather financial information: Obtain DexCom's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine DexCom's revenue streams: Identify DexCom's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research DexCom's industry and market trends, including the size of the market, growth rate, and competition.
- Establish DexCom's growth potential: Evaluate DexCom's management, business model, and growth potential.
- Determine DexCom's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate DexCom's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for DexCom Stock analysis
When running DexCom's price analysis, check to measure DexCom's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DexCom is operating at the current time. Most of DexCom's value examination focuses on studying past and present price action to predict the probability of DexCom's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DexCom's price. Additionally, you may evaluate how the addition of DexCom to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| CEOs Directory Screen CEOs from public companies around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |